Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Senator Markwayne Mullin (R-Oklahoma) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 31st, the Senator disclosed that they had sold between $1,001 and $15,000 ...

Investment analysts at William Blair dropped their Q1 2025 earnings estimates for shares of Abbott Laboratories in a report ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...